HIV lipodystrophy: Prevalence, severity and correlates of risk in Australia

HIV Medicine

Volumn 4, Issue 3, 2003, Pages 293-301

  Miller, John ^a   Carr, A ^b   Emery, S ^a   Law, M ^a   Mallal, S ^c   Baker, D ^d   Smith, D ^a   Kaldor, J ^a   Cooper, D A ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

^d NONE

Author keywords

Antiretrovirals; HIV; Lipodystrophy; Prevalence

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; LIVER ENZYME; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TESTOSTERONE; VIRUS RNA; ZALCITABINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE; ARTICLE; AUSTRALIA; BODY FAT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; LIPODYSTROPHY; LIPOHYPERTROPHY; LOGISTIC REGRESSION ANALYSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; OBESITY; OUTPATIENT DEPARTMENT; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK; SKINFOLD THICKNESS; VIRUS INHIBITION;

ADIPOSE TISSUE; ADULT; AGE FACTORS; ANTI-HIV AGENTS; AUSTRALIA; CROSS-SECTIONAL STUDIES; DENSITOMETRY, X-RAY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0042131994     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2003.00159.x     Document Type: Article

References (18)

1. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998 May 7; 12 (7): F51-F58.
2. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351: 871-875.
3. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. 'Buffalo hump' in men with HIV-1 infection. Lancet 1998; 351: 867-870.
4. Carr A, Samaras K, Thorisdottir A, Kaufmann G, Chisholm DJ, Cooper DA. Diagnosis, prediction and natural course of HIV protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus. Lancet 1999; 353: 2893-2899.
5. Lichtenstein K, Ward D, Moorman A et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001; 15: 1389-1398.
6. Jaquet D, Levine M, Ortega-Rodriguez E, Faye A, Polak M, Vilmer E, Levy-Marchal C. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 2000; 14 (14): 2123-2128.
7. Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N, Grinspoon S. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 1999; 84 (6): 1932-1937.
8. Heath KV, Hogg RS, Chan KJ, Harris M, Montessori V, O'Shaughnessy MV, Montaner JS. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001 January 26; 15 (2): 231-239.
9. Walli R, Herfort O, Michl GM et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired glucose tolerance in HIV-1 infected patients. AIDS 1998; 12 (15): F167-F173.
10. Henry K, Melroe H, Huebsch J et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 351: 1328.
11. Boubaker K, Sudre P, Flepp M et al. Hyperlactatemia and antiretroviral therapy in the Swiss HIV Cohort Study. Clin Infect Dis 2001; 33 (11): 1931-1937.
12. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000 July 10; 160 (13): 2050-2056.
13. Thiebaut R, Daucourt V, Mercie P et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection. Aquitaine Cohort, France, 1999. Clin Infect Dis 2000; 31 (6): 1482-1487.
14. Saint-Marc T, Partisani M, Poizot-Martin I et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000; 14: 37-49.
15. Kingsley L, Smit E, Riddler S et al. Prevalence of lipodystrophy and metabolic abnormalities in the Multicenter AIDS Cohort Study (MACS). 8th Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [Abstract 538].
16. Jeppeson J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight year follow-up in the Copenhagen male study. Circulation 1998; 97: 1029-1036.
17. National Centre in HIV Epidemiology and Clinical Research. HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia, Annual Surveillance Report 2002. Sydney, NSW, National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, 2002.
18. The Australian Observational Database. Rates of combination antiretroviral treatment change in Australia, 1997-2000. HIV Med 2002; 3: 28-36.